Rezolute, Inc. current report, 29 July 2016

Full document

SEC Filing Summary: AntriaBio, Inc. (Form 8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by AntriaBio, Inc. on July 29, 2016. The filing reports the completion of an additional close of a private placement transaction (PIPE Financing) pursuant to Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.

Key Financial Metrics

  • Gross Cash Proceeds: $460,000 (excluding placement agent compensation, transaction costs, fees, and expenses).
  • Securities Issued: 418,182 Units (comprising Class A and Class B Units).
  • Unit Price: $1.10 per Unit.
  • Warrant Exercise Price: $1.65 per share.
  • Warrant Term: 60 months (5 years) from the close date for investor warrants; 7 years for the Placement Agent warrant.
  • Debt and Liquidity: The filing text does not provide specific values for total debt, cash flow, or liquidity ratios beyond the proceeds from this transaction.

Material Changes and Transaction Details

The Company entered into Purchase Agreements with investors to issue Units consisting of common stock and warrants. The transaction structure included:

  • Class A Units: Issued to general investors; consisted of one share of common stock and one-half of one warrant.
  • Class B Units: Issued to investors who had previously invested in AntriaBio private placements and invested a minimum of $50,000 in this financing; consisted of one share of common stock and one full warrant.
  • Placement Agent Warrant: A financing warrant was issued to the Placement Agent exercisable for 7 years at $1.65 per share, containing cashless exercise rights and anti-dilution adjustments.

Guidance, Outlook, and Risks

The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. Key contingencies and obligations include:

  • Registration Rights: The Company agreed to file a registration statement within 90 days of the close to cover the Offered Shares, Warrant Shares, and Financing Warrant Shares.
  • Resale Restrictions: Securities were sold under an exemption from registration and may not be offered or sold in the United States absent registration or an applicable exemption.

Investor Verification Checklist

  • Verify the final net proceeds after deducting placement agent fees and transaction costs, as the $460,000 figure is gross.
  • Confirm the filing date and effectiveness of the registration statement required within 90 days of July 29, 2016.
  • Review the full text of the Purchase Agreement (Exhibit 10.1) and Warrant forms (Exhibits 4.1 and 4.2) for specific covenants and dilution protections.
  • Assess the impact of the 418,182 new shares and associated warrants on existing shareholder dilution.